NovoCure Ltd (NVCR) is a global oncology company focused on developing and commercializing innovative therapies for the treatment of cancer. The company's proprietary technology, Tumor Treating Fields (TTFields), is a novel anti-cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, ultimately leading to cell death in certain types of cancer cells.
NVCR's primary product, Optune, is a portable medical device that delivers TTFields to cancer patients' scalps via electrodes placed on the scalp. Optune has been approved by the FDA for the treatment of recurrent glioblastoma, a type of brain cancer, as well as for the treatment of malignant pleural mesothelioma.
The company is also actively researching the use of TTFields in the treatment of a variety of other solid tumors, including pancreatic, ovarian, and lung cancers, among others. Additionally, NVCR is exploring combination therapies that combine TTFields with other anti-cancer treatments, such as chemotherapy and immunotherapy.
NovoCure Ltd (NVCR) is a global oncology company focused on developing and commercializing innovative therapies for the treatment of cancer. The company's proprietary technology, Tumor Treating Fields (TTFields), is a novel anti-cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, ultimately leading to cell death in certain types of cancer cells.